Sarcoma Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 33.98%
(FY 2020)
- Profit 70.29%
(FY 2020)
- Ebitda -1.41%
(FY 2020)
- Net Worth 80.27%
(FY 2020)
- Total Assets 34.47%
(FY 2020)
About Sarcoma Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ankit Kumar, Swarn Singh, and Narendra Kumar serve as directors at the Company.
- CIN/LLPIN
U24239CH2015PTC035704
- Company No.
035704
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 2015
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sarcoma Remedies Private Limited offer?
Sarcoma Remedies Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Cardiovascular Drugs & Medication, Kidney Drugs, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Nutraceuticals & Dietary Supplements, Mineral Supplement, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Sarcoma Remedies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankit Kumar  | Director | 11-Feb-2021 | Current |
| Swarn Singh | Director | 21-Aug-2015 | Current |
| Narendra Kumar | Director | 21-Aug-2015 | Current |
Financial Performance of Sarcoma Remedies.
Sarcoma Remedies Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 33.98% increase. The company also saw a substantial improvement in profitability, with a 70.29% increase in profit. The company's net worth Soared by an impressive increase of 80.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sarcoma Remedies?
In 2020, Sarcoma Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sarcoma Remedies?
Unlock and access historical data on people associated with Sarcoma Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sarcoma Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sarcoma Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
